Clinical trial NCT00000125 - References

Glaucoma — Ocular Hypertension Treatment Study (OHTS)

Citation(s)

•   Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  Longitudinal and cross-sectional analyses of visual field progression in participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2010 Dec;128(12):1528-32. doi: 10.1001/archophthalmol.2010.292.
•   Bailey JN, Loomis SJ, Kang JH, Allingham RR, Gharahkhani P, Khor CC, Burdon KP, Aschard H, Chasman DI, Igo RP Jr, Hysi PG, Glastonbury CA, Ashley-Koch A, Brilliant M, Brown AA, Budenz DL, Buil A, Cheng CY, Choi H, Christen WG, Curhan G, De Vivo I, Fingert JH, Foster PJ, Fuchs C, Gaasterland D, Gaasterland T, Hewitt AW, Hu F, Hunter DJ, Khawaja AP, Lee RK, Li Z, Lichter PR, Mackey DA, McGuffin P, Mitchell P, Moroi SE, Perera SA, Pepper KW, Qi Q, Realini T, Richards JE, Ridker PM, Rimm E, Ritch R, Ritchie M, Schuman JS, Scott WK, Singh K, Sit AJ, Song YE, Tamimi RM, Topouzis F, Viswanathan AC, Verma SS, Vollrath D, Wang JJ, Weisschuh N, Wissinger B, Wollstein G, Wong TY, Yaspan BL, Zack DJ, Zhang K, Study EN; ANZRAG Consortium, Weinreb RN, Pericak-Vance MA, Small K, Hammond CJ, Aung T, Liu Y, Vithana EN, MacGregor S, Craig JE, Kraft P, Howell G, Hauser MA, Pasquale LR, Haines JL, Wiggs JL
  Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open-angle glaucoma. Nat Genet. 2016 Feb;48(2):189-94. doi: 10.1038/ng.3482. Epub 2016 Jan 11.
•   Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, Bourne WM
  Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006 Oct;25(9):1046-52.
•   Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  The incidence of retinal vein occlusion in the ocular hypertension treatment study. Ophthalmology. 2010 Mar;117(3):484-8. doi: 10.1016/j.ophtha.2009.08.022. Epub 2010 Jan 19.
•   Bhorade AM, Gordon MO, Wilson B, Weinreb RN, Kass MA; Ocular Hypertension Treatment Study Group
  Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study. Ophthalmology. 2009 Apr;116(4):717-24. doi: 10.1016/j.ophtha.2008.12.036. Epub 2009 Feb 25. Erratum in: Ophthalmology. 2009 May;116(5):822. Weinrab, Robert N [corrected to Weinreb, Robert N].
•   Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA; Ocular Hypertension Treatment Study Group
  The utility of the monocular trial: data from the ocular hypertension treatment study. Ophthalmology. 2010 Nov;117(11):2047-54. doi: 10.1016/j.ophtha.2010.02.020. Epub 2010 Aug 12.
•   Brandt JD, Beiser JA, Gordon MO, Kass MA; Ocular Hypertension Treatment Study (OHTS) Group
  Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Nov;138(5):717-22.
•   Brandt JD, Beiser JA, Kass MA, Gordon MO
  Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology. 2001 Oct;108(10):1779-88.
•   Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA; Ocular Hypertension Treatment Study Group
  Changes in central corneal thickness over time: the ocular hypertension treatment study. Ophthalmology. 2008 Sep;115(9):1550-6, 1556.e1. doi: 10.1016/j.ophtha.2008.02.001. Epub 2008 Apr 18.
•   Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA; Ocular Hypertension Treatment Study Group
  Adjusting intraocular pressure for central corneal thickness does not improve prediction models for primary open-angle glaucoma. Ophthalmology. 2012 Mar;119(3):437-42. doi: 10.1016/j.ophtha.2011.03.018. Epub 2011 Jun 25.
•   Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish RK 2nd, Piltz-Seymour JR, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology. 2006 Dec;113(12):2137-43. Epub 2006 Sep 25.
•   Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M; Ocular Hypertension Treatment Study Group
  Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2017 Feb;174:126-133. doi: 10.1016/j.ajo.2016.10.023. Epub 2016 Nov 7.
•   Chen Z, Wang K
  A gene-based test of association through an orthogonal decomposition of genotype scores. Hum Genet. 2017 Oct;136(10):1385-1394. doi: 10.1007/s00439-017-1839-y. Epub 2017 Sep 1.
•   Christopher M, Abràmoff MD, Tang L, Gordon MO, Kass MA, Budenz DL, Fingert JH, Scheetz TE
  Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension. Invest Ophthalmol Vis Sci. 2015 Jul;56(8):4470-9. doi: 10.1167/iovs.14-16142.
•   Coleman AL, Gordon MO, Beiser JA, Kass MA; Ocular Hypertension Treatment Study
  Baseline risk factors for the development of primary open-angle glaucoma in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004 Oct;138(4):684-5.
•   De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA
  Rate of visual field progression in eyes with optic disc hemorrhages in the ocular hypertension treatment study. Arch Ophthalmol. 2012 Dec;130(12):1541-6. doi: 10.1001/jamaophthalmol.2013.1137.
•   De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  Effect of treatment on the rate of visual field change in the ocular hypertension treatment study observation group. Invest Ophthalmol Vis Sci. 2012 Apr 2;53(4):1704-9. doi: 10.1167/iovs.11-8186.
•   Demirel S, De Moraes CG, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  The rate of visual field change in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2012 Jan 25;53(1):224-7. doi: 10.1167/iovs.10-7117.
•   Feuer WJ, Parrish RK 2nd, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO
  The Ocular Hypertension Treatment Study: reproducibility of cup/disk ratio measurements over time at an optic disc reading center. Am J Ophthalmol. 2002 Jan;133(1):19-28.
•   Gao F, Miller JP, Beiser JA, Xiong C, Gordon MO
  Predicting Clinical Binary Outcome Using Multivariate Longitudinal Data: Application to Patients with Newly Diagnosed Primary Open-Angle Glaucoma. J Biom Biostat. 2015 Oct;6(4). pii: 254. Epub 2015 Oct 26.
•   Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA, Gordon MO
  A Joint Model for Prognostic Effect of Biomarker Variability on Outcomes: long-term intraocular pressure (IOP) fluctuation on the risk of developing primary open-angle glaucoma (POAG). JP J Biostat. 2011 May 1;5(2):73-96.
•   Gao F, Miller JP, Xiong C, Beiser JA, Gordon M; The Ocular Hypertension Treatment Study (OHTS) Group
  A joint-modeling approach to assess the impact of biomarker variability on the risk of developing clinical outcome. Stat Methods Appt. 2011 Mar 1;20(1):83-100.
•   Gao F, Philip Miller J, Xiong C, Luo J, Beiser JA, Chen L, Gordon MO
  Estimating correlation between multivariate longitudinal data in the presence of heterogeneity. BMC Med Res Methodol. 2017 Aug 17;17(1):124. doi: 10.1186/s12874-017-0398-1.
•   Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  Series length used during trend analysis affects sensitivity to changes in progression rate in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2013 Feb 15;54(2):1252-9. doi: 10.1167/iovs.12-10218.
•   Gardiner SK, Demirel S, Gordon MO, Kass MA; Ocular Hypertension Treatment Study Group
  Seasonal changes in visual field sensitivity and intraocular pressure in the ocular hypertension treatment study. Ophthalmology. 2013 Apr;120(4):724-30. doi: 10.1016/j.ophtha.2012.09.056. Epub 2013 Jan 26.
•   Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA
  The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30.
•   Gordon MO, Beiser JA, Kass MA; Ocular Hypertension Treatment Study Group
  Is a history of diabetes mellitus protective against developing primary open-angle glaucoma? Arch Ophthalmol. 2008 Feb;126(2):280-1. doi: 10.1001/archophthalmol.2007.35.
•   Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA
  The 10-year incidence of glaucoma among patients with treated and untreated ocular hypertension. Arch Ophthalmol. 2011 Dec;129(12):1630-1. doi: 10.1001/archophthalmol.2011.337.
•   Gordon MO, Higginbotham EJ, Heuer DK, Parrish RK 2nd, Robin AL, Morris PA, Dunn DA, Wilson BS, Kass MA; Ocular Hypertension Treatment Study
  Assessment of the Impact of an Endpoint Committee in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2019 Mar;199:193-199. doi: 10.1016/j.ajo.2018.11.006. Epub 2018 Nov 22.
•   Gordon MO, Kass MA
  The Ocular Hypertension Treatment Study: design and baseline description of the participants. Arch Ophthalmol. 1999 May;117(5):573-83.
•   Gordon MO, Kass MA
  What We Have Learned From the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2018 May;189:xxiv-xxvii. doi: 10.1016/j.ajo.2018.02.016. Epub 2018 Mar 1. Review.
•   Herman DC, Gordon MO, Beiser JA, Chylack LT Jr, Lamping KA, Schein OD, Soltau JB, Kass MA; Ocular Hypertension Treatment Study (OHTS) Group
  Topical ocular hypotensive medication and lens opacification: evidence from the ocular hypertension treatment study. Am J Ophthalmol. 2006 Nov;142(5):800-10.
•   Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA; Ocular Hypertension Treatment Study Group
  The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004 Jun;122(6):813-20.
•   Johnson CA, Keltner JL, Cello KE, Edwards M, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E; Ocular Hypertension Study Group
  Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology. 2002 Mar;109(3):432-7.
•   Kass MA, Gordon MO, Kymes SM
  Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol. 2005 Jul;123(7):1021-2.
•   Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  Diabetes and glaucoma. Arch Ophthalmol. 2008 May;126(5):746-7. doi: 10.1001/archopht.126.5.746-b.
•   Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO
  The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30.
•   Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan J, Cello KE, Quigley HA, Budenz DL, Parrish RK, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology. 2006 Sep;113(9):1603-12.
•   Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan J, Levine RA, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma. 2007 Dec;16(8):665-9.
•   Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol. 2003 May;121(5):643-50. Erratum in: Arch Ophthalmol. 2008 Apr;126(4):561.
•   Keltner JL, Johnson CA, Levine RA, Fan J, Cello KE, Kass MA, Gordon MO
  Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005 Sep;123(9):1201-6.
•   Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO
  Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol. 2000 Sep;118(9):1187-94.
•   Khawaja AP, Cooke Bailey JN, Kang JH, Allingham RR, Hauser MA, Brilliant M, Budenz DL, Christen WG, Fingert J, Gaasterland D, Gaasterland T, Kraft P, Lee RK, Lichter PR, Liu Y, Medeiros F, Moroi SE, Richards JE, Realini T, Ritch R, Schuman JS, Scott WK, Singh K, Sit AJ, Vollrath D, Wollstein G, Zack DJ, Zhang K, Pericak-Vance M, Weinreb RN, Haines JL, Pasquale LR, Wiggs JL
  Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses. Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):5046-5052. doi: 10.1167/iovs.16-20017.
•   Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO; Ocular Hypertension Treatment Study Group (OHTS)
  Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2006 Jun;141(6):997-1008.
•   Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO
  The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model. Ophthalmology. 2012 Jul;119(7):1367-74. doi: 10.1016/j.ophtha.2012.01.054. Epub 2012 Apr 25.
•   Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO
  Effect of patient's life expectancy on the cost-effectiveness of treatment for ocular hypertension. Arch Ophthalmol. 2010 May;128(5):613-8. doi: 10.1001/archophthalmol.2010.83.
•   Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA; Ocular Hypertension Treatment Study Group
  Asymmetries and visual field summaries as predictors of glaucoma in the ocular hypertension treatment study. Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3896-903.
•   Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA; Ocular Hypertension Treatment Study Group
  Reduction in intraocular pressure after cataract extraction: the Ocular Hypertension Treatment Study. Ophthalmology. 2012 Sep;119(9):1826-31. doi: 10.1016/j.ophtha.2012.02.050. Epub 2012 May 16.
•   Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA; Ocular Hypertension Treatment Study Group
  Comparison of initial intraocular pressure response with topical beta-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2007 Apr;125(4):454-9.
•   Ocular Hypertension Treatment Study Group and the European Glaucoma Prevention Study Group
  The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals. Ophthalmology. 2008 Nov;115(11):2030-6. doi: 10.1016/j.ophtha.2008.06.036. Epub 2008 Sep 18.
•   Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group, Gordon MO, Torri V, Miglior S, Beiser JA, Floriani I, Miller JP, Gao F, Adamsons I, Poli D, D'Agostino RB, Kass MA
  Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007 Jan;114(1):10-9. Epub 2006 Nov 7.
•   Parrish RK 2nd, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz MC, Vandenbroucke R, Kass MA, Gordon MO; Ocular Hypertension Treatment Study Group
  Test-retest reproducibility of optic disk deterioration detected from stereophotographs by masked graders. Am J Ophthalmol. 2005 Oct;140(4):762-4.
•   Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO
  Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000 Oct;130(4):441-53.
•   Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR; Ocular Hypertension Treatment Study
  Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. Ophthalmology. 2015 Jan;122(1):79-86. doi: 10.1016/j.ophtha.2014.07.033. Epub 2014 Sep 7.
•   Schaefer JL, Lukowski ZL, Meyer AM, Leoncavallo AJ, Greer A, Martorana GM, Zou B, Shuster JJ, Sherwood MB
  Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Software Program in Ophthalmologists-in-Training. Am J Ophthalmol. 2016 Jul;167:88-95. doi: 10.1016/j.ajo.2016.03.031. Epub 2016 Mar 31.
•   Schaefer JL, Meyer AM, Rodgers CD, Rosenberg NC, Leoncavallo AJ, Lukowski ZL, Greer AB, Martorana GM, Zou B, Shuster JJ, Jay Katz L, Schuman JS, Kass MA, Sherwood MB
  Comparing glaucomatous disc change using stereo disc viewing and the MatchedFlicker programme in glaucoma experts and trainees. Br J Ophthalmol. 2018 Mar;102(3):358-363. doi: 10.1136/bjophthalmol-2017-310336. Epub 2017 Aug 16.
•   Scheetz TE, Faga B, Ortega L, Roos BR, Gordon MO, Kass MA, Wang K, Fingert JH
  Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. Ophthalmology. 2016 Dec;123(12):2527-2536. doi: 10.1016/j.ophtha.2016.08.036. Epub 2016 Oct 1.
•   Wang K
  Conditional asymptotic inference for the kernel association test. Bioinformatics. 2017 Dec 1;33(23):3733-3739. doi: 10.1093/bioinformatics/btx511.
•   Weinreb RN, Zangwill LM, Jain S, Becerra LM, Dirkes K, Piltz-Seymour JR, Cioffi GA, Trick GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA; OHTS CSLO Ancillary Study Group
  Predicting the onset of glaucoma: the confocal scanning laser ophthalmoscopy ancillary study to theOcular Hypertension Treatment Study. Ophthalmology. 2010 Sep;117(9):1674-83. doi: 10.1016/j.ophtha.2010.03.044. Epub 2010 Jul 14.
•   Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN; Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study
  The rate of structural change: the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Am J Ophthalmol. 2013 Jun;155(6):971-82. doi: 10.1016/j.ajo.2013.01.020. Epub 2013 Mar 14.
•   Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO
  Baseline topographic optic disc measurements are associated with the development of primary open-angle glaucoma: the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2005 Sep;123(9):1188-97.
•   Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA; Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study
  Racial differences in optic disc topography: baseline results from the confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study. Arch Ophthalmol. 2004 Jan;122(1):22-8.
•   Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA; OHTS CSLO Ancillary Study Group
  The confocal scanning laser ophthalmoscopy ancillary study to the ocular hypertension treatment study: study design and baseline factors. Am J Ophthalmol. 2004 Feb;137(2):219-27.

Ocular Hypertension Treatment Study (OHTS)

Details for clinical trial NCT00000125